Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1

Huan Fang,Wenlong Ren,Qiuxia Cui,Huichun Liang,Chuanyu Yang,Wenjing Liu,Xinye Wang,Xue Liu,Yujie Shi,Jing Feng,Ceshi Chen
DOI: https://doi.org/10.7554/elife.88483.3
IF: 7.7
2023-10-03
eLife
Abstract:Anti-tumor drug resistance is a challenge for human triple-negative breast cancer (TNBC) treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote TNBC cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin β4. Integrin β4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in TNBC. These results indicate that the Integrin β4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in TNBC.
biology
What problem does this paper attempt to address?